{"id":276,"date":"2013-10-02T16:13:05","date_gmt":"2013-10-02T16:13:05","guid":{"rendered":"http:\/\/www.dralexurology.com\/bladder-cancer\/?p=276"},"modified":"2013-10-27T01:54:19","modified_gmt":"2013-10-27T01:54:19","slug":"low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement","status":"publish","type":"post","link":"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/","title":{"rendered":"Low Rate of BCG use for Bladder Cancer – Major Opportunity for Healthcare Improvement"},"content":{"rendered":"

BCG treatment is known to benefit patients with bladder cancer. \u00a0Yet in the latest study only 22% of eligible patients receive the recommended BCG treatment<\/a>.<\/p>\n

The question is why?<\/strong><\/h2>\n

Every study has limitations. Certainly the limitations do not explain why almost 80% do not receive BCG treatment. It is a question of patient selection and physician awareness\/hesitance to administer BCG.<\/p>\n

[col type=”one-fourth”]\"shutterstock_116471599\"<\/a><\/p>\n

[\/col]<\/p>\n

[col type=”three-fourth last”]Very few patients are truly ineligible for BCG treatment – these are mostly patients who have absolute contraindications, mainly immunocompromise of some sort (UTI\/bleeding and trauma are temporary contraindications that usually go away in a few weeks). The absolute contraindications and other study limitations can account for at most 10-15% of patients with non-muscle invasive bladder cancer. That still leaves >50% of eligible population with bladder cancer who do not get a low cost highly beneficial treatment.[\/col]<\/p>\n

In my experience, I have not had a single patient who rejected an opportunity to receive BCG after an INFORMED CONSENT about its benefits and risks. \u00a0Why? \u00a0Patients are very rational. \u00a0They know that an ounce of prevention is better than a pound of treatment.<\/p>\n

Some of my patients have stopped BCG after initiating it because of tolerance or side effect issues. Some were not able to start it because of other medical issues, intervening contraindications. \u00a0 Many of the elderly and frail patients have a more extended period over which they end up getting the induction 6 week course of treatment – some get it over 12 weeks.\u00a0<\/span><\/p>\n

Yet overall in my practice close to 90% of eligible practice at least initiate BCG treatment<\/a>; more than 80% complete induction BCG course either at a full or reduced dose. \u00a0Vast majority of these CHOOSE to continue maintenance BCG treatment despite tolerable side effects because of the INFORMED UNDERSTANDING OF BENEFITS of BCG treatment<\/strong>.<\/p>\n

What is the solution to the national problem?<\/h2>\n

I believe similar to a smoking campaign, an awareness campaign for bladder patients “Ask Your Doctor About BCG”<\/strong> will be the best impetus for the physicians to offer BCG. \u00a0Physician awareness campaign<\/strong>, perhaps incorporated in the next #ChooseWisely<\/strong> campaign of THINGS TO DO.<\/p>\n

If all fails, perhaps increasing reimbursement<\/strong> to make it extremely lucrative to administer BCG will do the trick. \u00a0Because BCG is so cost effective, providing financial incentives will still lead to significant cost savings. \u00a0Financial incentives always work well (Look at how much infighting there is for Radiation Therapy dollars – everyone – hospitals – RadOnc, Urologists, etc – wants to have the monopoly to give it). \u00a0The risks of BCG are a sufficient disincentive for physicians not to administer it to those who do not qualify.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

BCG treatment is known to benefit patients with bladder cancer. \u00a0Yet in the latest study only 22% of eligible patients receive the recommended BCG treatment. The question is why? Every study has limitations. Certainly the limitations do not explain why almost 80% do not receive BCG treatment. It is a question of patient selection and […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[31,10,32],"class_list":["post-276","post","type-post","status-publish","format-standard","hentry","category-bcg-treatment-news","tag-bcg-therapy","tag-cis-of-the-bladder","tag-tcc-bladder"],"yoast_head":"\nLow Rate of BCG use for Bladder Cancer - Major Opportunity for Healthcare Improvement - Bladder Cancer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alex Shteynshlyuger MD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/\",\"url\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/\",\"name\":\"Low Rate of BCG use for Bladder Cancer - Major Opportunity for Healthcare Improvement - Bladder Cancer\",\"isPartOf\":{\"@id\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-content\/uploads\/sites\/7\/2013\/10\/shutterstock_116471599-150x150.jpg\",\"datePublished\":\"2013-10-02T16:13:05+00:00\",\"dateModified\":\"2013-10-27T01:54:19+00:00\",\"author\":{\"@id\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/#\/schema\/person\/ebf5540308ae0ef79978bd465bcfc26f\"},\"breadcrumb\":{\"@id\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/#primaryimage\",\"url\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-content\/uploads\/sites\/7\/2013\/10\/shutterstock_116471599.jpg\",\"contentUrl\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-content\/uploads\/sites\/7\/2013\/10\/shutterstock_116471599.jpg\",\"width\":500,\"height\":375},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Low Rate of BCG use for Bladder Cancer – Major Opportunity for Healthcare Improvement\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/#website\",\"url\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/\",\"name\":\"Bladder Cancer\",\"description\":\"Fellowship Trained Urologist Optimizes Cancer Care\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/#\/schema\/person\/ebf5540308ae0ef79978bd465bcfc26f\",\"name\":\"Alex Shteynshlyuger MD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0b99ebe6e8dd34d37b0fa8940b69588a24cc2397c3a15707a5e7df31707dd5af?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0b99ebe6e8dd34d37b0fa8940b69588a24cc2397c3a15707a5e7df31707dd5af?s=96&d=mm&r=g\",\"caption\":\"Alex Shteynshlyuger MD\"},\"url\":\"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Low Rate of BCG use for Bladder Cancer - Major Opportunity for Healthcare Improvement - Bladder Cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/","twitter_misc":{"Written by":"Alex Shteynshlyuger MD","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/","url":"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/","name":"Low Rate of BCG use for Bladder Cancer - Major Opportunity for Healthcare Improvement - Bladder Cancer","isPartOf":{"@id":"http:\/\/www.dralexurology.com\/bladder-cancer\/#website"},"primaryImageOfPage":{"@id":"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/#primaryimage"},"image":{"@id":"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/#primaryimage"},"thumbnailUrl":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-content\/uploads\/sites\/7\/2013\/10\/shutterstock_116471599-150x150.jpg","datePublished":"2013-10-02T16:13:05+00:00","dateModified":"2013-10-27T01:54:19+00:00","author":{"@id":"http:\/\/www.dralexurology.com\/bladder-cancer\/#\/schema\/person\/ebf5540308ae0ef79978bd465bcfc26f"},"breadcrumb":{"@id":"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/#primaryimage","url":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-content\/uploads\/sites\/7\/2013\/10\/shutterstock_116471599.jpg","contentUrl":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-content\/uploads\/sites\/7\/2013\/10\/shutterstock_116471599.jpg","width":500,"height":375},{"@type":"BreadcrumbList","@id":"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/low-rate-bcg-use-bladder-cancer-major-opportunity-healthcare-improvement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/www.dralexurology.com\/bladder-cancer\/"},{"@type":"ListItem","position":2,"name":"Low Rate of BCG use for Bladder Cancer – Major Opportunity for Healthcare Improvement"}]},{"@type":"WebSite","@id":"http:\/\/www.dralexurology.com\/bladder-cancer\/#website","url":"http:\/\/www.dralexurology.com\/bladder-cancer\/","name":"Bladder Cancer","description":"Fellowship Trained Urologist Optimizes Cancer Care","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/www.dralexurology.com\/bladder-cancer\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"http:\/\/www.dralexurology.com\/bladder-cancer\/#\/schema\/person\/ebf5540308ae0ef79978bd465bcfc26f","name":"Alex Shteynshlyuger MD","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/www.dralexurology.com\/bladder-cancer\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0b99ebe6e8dd34d37b0fa8940b69588a24cc2397c3a15707a5e7df31707dd5af?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0b99ebe6e8dd34d37b0fa8940b69588a24cc2397c3a15707a5e7df31707dd5af?s=96&d=mm&r=g","caption":"Alex Shteynshlyuger MD"},"url":"http:\/\/www.dralexurology.com\/bladder-cancer\/news\/author\/admin\/"}]}},"_links":{"self":[{"href":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-json\/wp\/v2\/posts\/276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-json\/wp\/v2\/comments?post=276"}],"version-history":[{"count":2,"href":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-json\/wp\/v2\/posts\/276\/revisions"}],"predecessor-version":[{"id":281,"href":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-json\/wp\/v2\/posts\/276\/revisions\/281"}],"wp:attachment":[{"href":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-json\/wp\/v2\/media?parent=276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-json\/wp\/v2\/categories?post=276"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.dralexurology.com\/bladder-cancer\/wp-json\/wp\/v2\/tags?post=276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}